Novartis drops PhII Parkinson's program
This article was originally published in Scrip
Executive Summary
Novartis has discontinued development of the investigative compound AFQ056 to treat the jerky motions and tics that are a side-effect of treatment with levodopa in patients with Parkinson's disease. The firm had been planning to file its first regulatory approval submissions in this indication in 2015. However, the product failed to show efficacy in Parkinson's disease levodopa-induced dyskinesia (PD-LID) in recent Phase II studies.
You may also be interested in...
Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse
The biotech has persuaded its fellow Swiss firm that it can advance mavoglurant, a Novartis drug that has failed in Parkinson’s and Fragile X syndrome, for cocaine use and neurodevelopmental disorders.
Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.
Addex Completes Turnaround, Prepares For Phase III Dyskinesia Study
Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.